Scisparc Stock In The News
| SPRC Stock | USD 0.25 0.04 13.79% |
Our overall analysis of Scisparc's news coverage and content from conventional and social sources shows investors' bearish mood towards Scisparc. The specific impact of Scisparc news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Scisparc's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Scisparc headlines in addition to utilizing other, more conventional financial analysis modules. Check out Scisparc Backtesting and Scisparc Hype Analysis. For information on how to trade Scisparc Stock refer to our How to Trade Scisparc Stock guide.
Scisparc |
Scisparc Today Top News and Investor Outlook
Scisparc Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Scisparc and other traded companies coverage with news coverage. We help investors stay connected with Scisparc headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Scisparc Stock performance. Please note that trading solely based on the Scisparc hype is not for everyone as timely availability and quick action are needed to avoid losses.
Scisparc stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Scisparc earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Scisparc that are available to investors today. That information is available publicly through Scisparc media outlets and privately through word of mouth or via Scisparc internal channels. However, regardless of the origin, that massive amount of Scisparc data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Scisparc news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Scisparc relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Scisparc's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Scisparc alpha.
Scisparc Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Scisparc Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months ... at news.google.com
20th of November 2024
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks at news.google.com
20th of November 2024
Hoth Up on Bitcoin Buy - Baystreet.ca at news.google.com
19th of November 2024
Biotechnology Reagents Kits Market to Reach USD 1442.11 Billion by 2032 at a CAGR of 10.97... at kalkinemedia.com
19th of November 2024
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Out... at finance.yahoo.com
19th of November 2024
CHMP Endorses AstraZenecas Tagrisso for Expanded Use in NSCLC at zacks.com
19th of November 2024
Atico Reports Consolidated Financial Results for Third Quarter of 2024 at finance.yahoo.com
19th of November 2024
Revolution Beauty Group Reaches New 12-Month Low Time to Sell at thelincolnianonline.com
18th of November 2024
Cardio Diagnostics shareholders approve key proposals at investing.com
18th of November 2024
AAP Replaces Kailash Gahlot With Another Jat face In Delhi Cabinet at ndtv.com
15th of November 2024
We Think Kiora Pharmaceuticals Healthy Earnings Might Be Conservative at finance.yahoo.com
14th of November 2024
Walleye Capital LLC Acquires New Stake in Unicycive Therapeutics Inc at gurufocus.com
14th of November 2024
The state that cleared the way for sports gambling now may ban prop bets on college athlet... at apnews.com
13th of November 2024
BioNTech Acquires Pumeast Biotechnology for 800 Million at gurufocus.com
13th of November 2024
Instil Bio files for 200M mixed securities shelf at seekingalpha.com
12th of November 2024
Unicycive shares hold as FDA reviews new drug application at investing.com
12th of November 2024
CytomX Therapeutics SWOT analysis biotech stocks potential in cancer treatment at investing.com
12th of November 2024
Nuvation Bios SWOT analysis taletrectinib drives stock potential amid challenges at investing.com
12th of November 2024
Acquisition by Melissa Tosca of 100 shares of Kiora Pharmaceuticals at 5.25 subject to Rul... at investing.com
8th of November 2024
Cadrenal Therapeutics reports Q3 results at seekingalpha.com
7th of November 2024
Nuvation Bio GAAP EPS of -0.15, revenue of 0.7M at seekingalpha.com
6th of November 2024
CytomX Q3 2024 Earnings Preview at seekingalpha.com
6th of November 2024
With Harris down, Newsoms political stock rises again in California and beyond at aol.com
5th of November 2024
Dow Jumps 400 Points Yum Brands Posts Downbeat Earnings at benzinga.com
4th of November 2024
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscree... at news.google.com
4th of November 2024
Fujian Wanchen Biotechnology Groups Strong Earnings Are Of Good Quality at simplywall.st
4th of November 2024
Disposition of 150000 shares by Jeff Cole of Cadrenal Therapeutics, at 0.94 subject to Rul... at MacroaxisInsider
4th of November 2024
INVITATION TIL DFDS 3. KVT. 2024 TELEKONFERENCE at globenewswire.com
17th of October 2024
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Ob... at globenewswire.com
16th of October 2024
Robert Mashal Spends US220k On Nuvation Bio Shares at simplywall.st
14th of October 2024
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonat... at globenewswire.com
11th of October 2024
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com at news.google.com
9th of October 2024
National Poll on Perceptions of Mental Health and Suicide Prevention Reveals Most U.S. Adu... at finance.yahoo.com
8th of October 2024
Virios Therapeutics Soars Over 33 percent on Merger Announcement at gurufocus.com
8th of October 2024
Acquisition by Mashal Robert of tradable shares of Nuvation Bio at 2.195 subject to Rule 1... at MacroaxisInsider
1st of October 2024
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for M... at businesswire.com
1st of October 2024
Virios Therapeutics stock hits 52-week low at 0.15 - Investing.com at news.google.com
30th of September 2024
Acquisition by Burton Paul Frederick of 18686 shares of Cardio Diagnostics at 0.22 subject... at MacroaxisInsider
30th of September 2024
Kiora Pharmaceuticals, Inc. Short Interest Down 13.3 percent in September at thelincolnianonline.com
26th of September 2024
SciSparc signs LOI to sell entire ownership in MitoCareX at seekingalpha.com
24th of September 2024
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fa... at finance.yahoo.com
24th of September 2024
Revelation Biosciences Gemini Induces Dose Dependent Significant Increases in IL-10 at businesswire.com
19th of September 2024
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Off... at finance.yahoo.com
18th of September 2024
Acquisition by Bronson Crouch of 50000 shares of Instil Bio at 66.1 subject to Rule 16b-3 at MacroaxisInsider
17th of September 2024
Potential Catalyst Right Around The Corner CMS To Announce Preliminary Medicare Payment Fo... at finance.yahoo.com
16th of September 2024
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Pa... at globenewswire.com
16th of September 2024
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market M... at finance.yahoo.com
11th of September 2024
SciSparc extends additional loan of 1.85M to AutoMax at seekingalpha.com
5th of September 2024
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment o... at finance.yahoo.com
5th of September 2024
Acquisition by Hollander David of 1778 shares of Kiora Pharmaceuticals at 4.35 subject to ... at MacroaxisInsider
13th of August 2024
VIRI Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024 at finance.yahoo.com
8th of August 2024
VIRI Stock Earnings Virios Therapeutics Beats EPS for Q2 2024 at investorplace.com
24th of May 2024
YS Biopharma to change legal name to LakeShore Biopharma at seekingalpha.com
18th of July 2023
Neoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal NLTX at marketwatch.com
10th of July 2023
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER... at news.google.com
28th of June 2023
Monkeypox Vaccine Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vac... at finance.yahoo.com
23rd of June 2023
Why Is Castellum Stock Up 64 percent Today at investorplace.com
9th of June 2023
Calif. Atty To Pay 183K Over SECs Founders Shares Claims - Law360 at news.google.com
23rd of May 2023
Selling Blue Water Biotech Shares at a Lower Price Than Current Market Value May Have Been... at simplywall.st
18th of May 2023
OncoSec Announces Closing of 1.33 Million Registered Direct Offering Priced At-The-Market ... at finance.yahoo.com
3rd of May 2023
Salzhauer Michael Sells 275,483 Shares of OncoSec Medical Incorporated at thelincolnianonline.com
27th of April 2023
Hillstream BioPharma, Inc. Short Interest Update at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Scisparc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Scisparc's short interest history, or implied volatility extrapolated from Scisparc options trading.
Check out Scisparc Backtesting and Scisparc Hype Analysis. For information on how to trade Scisparc Stock refer to our How to Trade Scisparc Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scisparc. If investors know Scisparc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scisparc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.28) | Revenue Per Share 1.357 | Quarterly Revenue Growth (0.57) | Return On Assets (0.39) | Return On Equity (0.86) |
The market value of Scisparc is measured differently than its book value, which is the value of Scisparc that is recorded on the company's balance sheet. Investors also form their own opinion of Scisparc's value that differs from its market value or its book value, called intrinsic value, which is Scisparc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scisparc's market value can be influenced by many factors that don't directly affect Scisparc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scisparc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scisparc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scisparc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.